310 related articles for article (PubMed ID: 26056189)
1. Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion.
Müssigbrodt A; John S; Kosiuk J; Richter S; Hindricks G; Bollmann A
Europace; 2016 Jan; 18(1):51-6. PubMed ID: 26056189
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
Savelieva I; Graydon R; Camm AJ
Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
Beatch GN; Mangal B
BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
[TBL] [Abstract][Full Text] [Related]
4. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
Pohjantähti-Maaroos H; Hyppölä H; Lekkala M; Sinisalo E; Heikkola A; Hartikainen J
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):114-120. PubMed ID: 28849946
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
Ma W; Guo X; Wang Q; Sun G; Wang J
J Cardiovasc Pharmacol; 2020 Jul; 76(1):32-41. PubMed ID: 32251022
[TBL] [Abstract][Full Text] [Related]
6. Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion.
Sticherling C; Behrens S; Kamke W; Stahn A; Zabel M
Europace; 2005 Nov; 7(6):546-53. PubMed ID: 16216756
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
[TBL] [Abstract][Full Text] [Related]
9. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
[TBL] [Abstract][Full Text] [Related]
10. Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone.
Van Noord T; Van Gelder IC; Schoonderwoerd BA; Crijns HJ
Am J Cardiol; 2000 Dec; 86(12):1384-5, A5. PubMed ID: 11113420
[TBL] [Abstract][Full Text] [Related]
11. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.
Naegeli B; Straumann E; Bertel O
Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188
[TBL] [Abstract][Full Text] [Related]
12. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
Stoneman P; Gilligan P; Mahon P; Sheahan R
Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
[TBL] [Abstract][Full Text] [Related]
13. Effect of atrial fibrillation duration on probability of immediate recurrence after transthoracic cardioversion.
Oral H; Ozaydin M; Sticherling C; Tada H; Scharf C; Chugh A; Lai SW; Pelosi F; Knight BP; Strickberger SA; Morady F
J Cardiovasc Electrophysiol; 2003 Feb; 14(2):182-5. PubMed ID: 12693502
[TBL] [Abstract][Full Text] [Related]
14. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Camm AJ; Capucci A; Hohnloser SH; Torp-Pedersen C; Van Gelder IC; Mangal B; Beatch G;
J Am Coll Cardiol; 2011 Jan; 57(3):313-21. PubMed ID: 21232669
[TBL] [Abstract][Full Text] [Related]
15. [Vernakalant for the conversion of atrial fibrillation of recent onset].
Seoane L; Baranchuk A; Conde D
Medicina (B Aires); 2015; 75(4):239-44. PubMed ID: 26339882
[TBL] [Abstract][Full Text] [Related]
16. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
[TBL] [Abstract][Full Text] [Related]
17. Early recurrence of atrial fibrillation after external cardioversion.
Yu WC; Lin YK; Tai CT; Tsai CF; Hsieh MH; Chen CC; Hsu TL; Ding YA; Chang MS; Chen SA
Pacing Clin Electrophysiol; 1999 Nov; 22(11):1614-9. PubMed ID: 10598964
[TBL] [Abstract][Full Text] [Related]
18. [Effects of pretreatment with amiodarone infusion in patients with persistent atrial fibrillation submitted to external electrical cardioversion: a single center experience].
Maffè S; Paffoni P; Perucca A; Dellavesa P; Parravicini U; Nicali R; Bielli M; Paino AM; Signorotti F; Franchetti Pardo N; Zenone F; Zanetta M
G Ital Cardiol (Rome); 2008 Jul; 9(7):504-8. PubMed ID: 18678217
[TBL] [Abstract][Full Text] [Related]
19. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
Guerra F; Matassini MV; Scappini L; Urbinati A; Capucci A
Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1067-75. PubMed ID: 25096598
[TBL] [Abstract][Full Text] [Related]
20. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
Conde D
Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
